FINAL SAVINGS ENG IN
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Congress Center,
Basel Switzerland
Coming to London: 2024 Agenda Topics Preliminary Agenda Just Launched!
Brand New Topic Streams On The Latest In Antibody Science
Each year Antibody Engineering & Therapeutics Europe's scientific agenda brings you 100+ leading antibody and protein engineering scientists diving into the critical updates within the industry.
Take a look below to see the confirmed session themes and chairs for 2024.
Fc Engineering
Session Co-Chairs:
Sally Ward, Ph.D., Professor and Director, University of Southampton,United Kingdom
Robert de Jong, Ph.D., Director Antibody Research & Technology, Genmab, The Netherlands
Novel Approaches to Antibody Discovery
Session Chair:
James A. Ernst, Ph.D., Vice President, Head of Development Sciences, Xencor
Challenges in Discovery & Optimization of Multispecific Antibodies
Session Chair:
Rene Hoet, Ph.D., Chief Innovations Officer, FairJourney Biologics, Portugal
Agonist Antibodies
Session Chair:
Stephen Beers, Ph.D., Professor of Immunology and Immunotherapy, Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton, United Kingdom
Conditionally Active Biotherapeutics
Session Chair:
Benjamí Oller-Salvia, Ph.D., Assistant Professor at IQS Barcelona, Ramon, Llull University, Spain
Computational Approaches to Antibody Discovery and Optimization
Session Chair:
Cédric R. Weber, Ph.D., Director of Data Science and Bioinformatics, Alloy Therapeutics, Inc., Switzerland
Co-Stimulatory Antibodies and Combination Approaches in Oncology
Session Chair:
Katherine Harris, Ph.D., Chief Development Officer, Rondo Therapeutics
Antibody Theranostics: New Horizons
Session Chair:
Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom
Emerging Modalities: ADCs, Degraders and Beyond
Session Chair:
James Hunt, Director, R&D Biologics Engineering, AstraZeneca
Early Confirmed 2024 Keynote Speakers
Antibody Engineering & Therapeutics Europe brings you pioneers within the antibody community and a programme that is second-to-none. This is your opportunity to put your questions to the who's who in the antibody industry.